An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Key claim: A phase I/II dose-finding study is evaluating the optimal dose of N-acetylcysteine in patients with myeloproliferative neoplasms.
Abstract
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
Why this matters
This is the first formal dose-finding clinical trial of NAC specifically in MPN patients, moving antioxidant supplementation in this population from purely mechanism-plausible territory toward direct (if still early) MPN evidence. Because MPN patients frequently self-supplement antioxidants based on oxidative-stress rationale, an MPN-specific dose study is meaningful even pre-results — it will eventually anchor a tier-upgrade from mechanism-plausible to mpn-direct on this topic. Until results report, claims about NAC benefit must remain at trial-early/mechanism-plausible and not be promoted.